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Surface plasmon resonance (SPR) is one of the primary biophysical methods for the screening of low
molecular weight ‘fragment’ libraries, due to its low protein consumption and ‘label-free’ methodology.
SPR biosensor interaction analysis is employed to both screen and conﬁrm the binding of compounds in
fragment screening experiments, as it provides accurate information on the afﬁnity and kinetics of
molecular interactions. The most advanced application of the use of SPR for fragment screening is against
membrane protein drug targets, such G-protein coupled receptors (GPCRs). Biophysical GPCR assays
using SPR have been validated with pharmacological measurements approximate to cell-based methods,
yet provide the advantage of biophysical methods in their ability to measure the weak afﬁnities of low
molecular weight fragments. A number of SPR fragment screens against GPCRs have now been disclosed
in the literature. SPR fragment screening is proving versatile to screen both thermostabilised GPCRs and
solubilised wild type receptors. In this chapter, we discuss the state-of-the-art in GPCR fragment
screening by SPR and the technical considerations in performing such experiments.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction to fragment screening
Fragment-based drug discovery (FBDD) has a proven ability to
contribute to the discovery of approved drugs and advanced
investigational drugs (Congreve et al., 2008; Schulz and Hubbard,
2009; Chessari and Woodhead, 2009). Over the past 15 years,
FBDD, has become one of the primary strategies for discovering
small molecule ligands, alongside analogue-based drug design
(Wermuth et al., 2006), structure-based drug design (Blundell,
1996) and high-throughput screening (HTS) (Spencer, 1998;
Pereira and Williams, 2007). The principles of FBDD are based on
three key tenets. The ﬁrst tenet is that a small number of low
molecular weight compounds e (known as ‘fragments’) can
represent large areas of chemical space (Pollack et al., 2011). The
second tenet is that as the molecular weight and thus complexity of
a molecule increases, the probability of an unfavourable interaction
also increases (Hann et al., 2001). Thus, low molecular weight
fragments are proposed to be less selective than larger compounds
and are therefore capable of binding to a larger number of proteins
than conventional ‘drug-size’ compounds (Hopkins et al., 2006). In
contrast to conventional high-throughput screening, where com-
pound libraries of 100,000 to 1,000,000 are commonly screened,
FBDD usually involves screening small libraries containing only 500kins).
Ltd. This is an open access article uto 2000 compounds. However, the primary difference between
conventional HTS compound collections and fragment screening
libraries is the molecular mass of the constituent compounds and
their expected afﬁnities. The compounds screened in HTS are
typically of molecular mass 350 Dae500 Da, equivalent to 27 to 38
non-hydrogen atoms (Hopkins et al., 2004). The expected afﬁnity
for ‘hit’ compounds detected in a conventional HTS assay is in the
nanomolar to low micromolar range. However, compounds
selected for fragment screening are low molecular weight com-
pounds of 8e23 non-hydrogen atoms, equivalent to
100 Dae300 Da (‘fragments’) with the expected afﬁnities of ‘hits’
ranging from micromolar to millimolar (Hajduk and Greer, 2007).
The third tenet is that despite the low binding afﬁnity that is often
observed for fragment ‘hit’ molecules, compounds can be opti-
mised into high afﬁnity ligands. To improve afﬁnity and selectivity
of the initial ‘hit’ fragments, the optimisation process tends to in-
crease the molecular mass and atom count. With the need to add a
signiﬁcant additional number of ‘heavy’ atoms (i.e. non-hydrogen
atoms) in order to optimise a fragment into a potential investiga-
tional drug candidate, the scale of the optimisation process could be
considered daunting. To overcome this challenge efﬁciently,
fragment-based drug discovery is usually informed by structure-
based drug design methods. The determination of X-ray crystal
structures of the fragments bound to their target protein complexes
is often crucial to enable efﬁcient optimisation of fragments.
Despite the major difference in molecular mass between fragments
and their resulting optimised compound, it is not uncommon in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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in a highly efﬁcient manner.
The lowmolecular mass of fragment compounds tends to result
in binding interactions with low afﬁnity, thus compounds require
screening at high concentrations to be detected. High concentra-
tion screening of fragment libraries using conventional biochem-
ical assays has been undertaken. However, secondary biophysical
screening is needed to conﬁrm and validate genuine hits, due to
the large false positive hit rate encountered in high concentration
biochemical assays. Therefore, in order to detect low afﬁnity in-
teractions, fragment screening usually employs highly sensitive
biophysical techniques as primary screening methodologies. The
range of biophysical technologies applied to fragment screening
includes various NMR methods (Shuker et al., 1996; Fejzo et al.,
1999; Mayer and Meyer, 1999; Dalvit et al., 2000; Vanwetswinkel
et al., 2005), direct observation by X-ray crystallography of crys-
tals exposed to mixtures (Congreve et al., 2003) and solutions
(English et al., 1999) of fragments, mass spectrometry, isothermal
titration calorimetry (Ladbury et al., 2010), protein thermal shift
(Kranz et al., 2011), afﬁnity capillary electrophoresis (Lewis et al.,
2004), weak afﬁnity chromatography (Duong-Thi et al., 2011) and
label-free biosensor methods (Pr€oll et al., 2009; Rawlins, 2010)
such as Optical Waveguide Grating (OWG, Corning Epic) and
reﬂectometric interference spectroscopy (RIfS, ForteBio Octet).
However, in recent years surface plasmon resonance (SPR) has
emerged as one of the most popular and widely applied fragment
screening technologies and it is application of SPR to fragment
screening that we shall primarily concern ourselves within this
chapter.
2. Surface plasmon resonance
Surface plasmon resonance (SPR) is an optical biosensor
detection method that measures the change in refractive index at
the surface interface that occurs during a binding event (Huber
and Mueller, 2006). SPR is classiﬁed as a biophysical, ‘label-free’
method as it quantiﬁes the direct molecular interactions, without
the need for inferring the measurement indirectly via the
displacement of a ‘labelled’ ligand (i.e. radioisotope or ﬂuorescence
label). SPR biosensors measure the interactions between mole-
cules immobilised on the biosensor surface and molecules in so-
lution, in real time. The immobilisation of molecules to the
biosensor surface can be achieved using covalent coupling
methods such as amine, thiol and aldehyde coupling, for example,
or by non-covalent coupling methods employing metal chelation,
monoclonal antibody tags or other afﬁnity tags, such as biotin/
streptavidin.
SPR biosensor interaction analysis is employed to both screen
and conﬁrm the binding of compounds in fragment screening ex-
periments, as it provides accurate information on the afﬁnity, ki-
netics and even the thermodynamics of the fragment-protein
binding interaction. SPR biosensor assays can be used to determine
a number of interaction parameters that characterise the formation
of a molecular complex: association rate (ka); dissociation rate (kd);
afﬁnity (KD) (by equilibrium or kinetic analysis) and the stoichi-
ometry of the interaction.
Analysis of binding interactions by SPR can identify hit com-
pounds with slow dissociation rates (Navratilova and Hopkins,
2010). Drugs with slow dissociation rates often show superior
clinical efﬁcacy (Swinney, 2008). Therefore, the ability to identify
fragments with slow dissociations rates may help prioritise starting
points for lead optimisation. SPR analysis can also be used to
determine the thermodynamic parameters of the interaction (DG,
DH and DS) using the van't Hoff equation, by measuring the KD over
a temperature range (Myszka, 2000; Navratilova et al., 2007;Papalia et al., 2008). The equilibrium dissociation and thermody-
namic constants determined by SPR analysis correlate extremely
well with the values determined using isothermal titration calo-
rimetry, with the use of signiﬁcantly less protein (Navratilova et al.,
2007). This facility has not yet beenwidely adopted in SPR fragment
validation and conﬁrmation studies but may provide an interesting
area for development as it has been argued that fragments that
bind with predominately enthalpic energies may superior starting
points for optimisation (Freire, 2008).
3. SPR fragment screening
SPR biosensor assays are often used in fragment-based drug
discovery as an orthogonal, complementary technique to conﬁrm
and validate the direct measurement of the kinetics and afﬁnity of
fragment hits discovered by other screening methods (Huber,
2005; Geschwindner et al., 2007; Godemann et al., 2009; Cole
et al., 2010). However, in recent years SPR biosensor screening
has become a primary screening method for fragment-based drug
discovery (Giannetti, 2011), as it has several practical advantages
over other techniques.
SPR analysis provides both the throughput and sensitivity for
conducting the high throughput screening of fragment libraries as
well as the conﬁrmation and validation of the fragment hits, using a
single methodology. SPR analysis is also able to provide accurate
measurements of afﬁnity and kinetics to aid the identiﬁcation and
prioritisation of fragment hits.
Additionally, SPR assay development and screening can often be
developed quickly, compared to developing biochemical HTS assays
or generating high resolution, crystallographic systems. Thus,
fragment binding information can be acquired quickly and early in
a drug discovery programme. Such fragments may themselves aid
crystallisation. The speed of assay development is also aided by the
low protein consumption of SPR fragment screens. Entire SPR
fragment screening projects, including assay development, the
screening campaign and hit validation require as little as 25e100 mg
of protein. The protein consumption of an SPR fragment screening
campaign can be 10-folde1000-fold less than is required by other
biochemical and biophysical fragment screening methods. If puri-
ﬁed, untagged protein is available, direct coupling methods can be
used to immobilise the target protein on the biosensor surface.
However, the success of developing directly coupled SPR assays
increases if the target protein is puriﬁed to the high standards
required for other biophysical techniques, such as crystallisation.
The engineering of assay protein with speciﬁc afﬁnity tags can aid
puriﬁcation on the SPR chip itself by immobilisation of the target
protein onto the biosensor surface, even for unpuriﬁed tagged
protein from cell pellets or lysates.
The throughput of the current generation of marketed
biosensor instruments enables biosensor-based screening of
fragment libraries in a timeframe of around one day to two weeks.
The total experimental time is determined by the number of
compounds in the fragment library, number of concentration
measurements screened per compound, the stability of the protein
and type of instrument. For example using stable, puriﬁed or
tagged protein immobilised on a high-throughput GE Biacore 4000
or a Sierra Sensors MASS-1 instrument, with appropriate test li-
gands for assay development, it is entirely possible to screen and
conﬁrm fragment hits from a few micrograms of protein within a
few days.
4. Experimental design considerations
The objective of SPR assay design, in order to run a high
throughput biophysical screen on large numbers of compounds, is
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2011, Danielson, 2009. In order to achieve this objective, the SPR
assay needs to be designed and validated to accurately determine
the binding parameters by minimising the false positive rate and
the false negative rate. Details on SPR fragment screening protocols
are described by Giannetti (2011), Danielson (2009) and
Navratilova and Hopkins (2010).
Successful SPR fragment screening is dependent on the imple-
mentation of data quality control methods and the scaling and
normalisation of the primary screening data in order to identify hits
and remove false positives. Experimental design can reduce the
false positive data detection rate by designing an appropriate
referencing protocol for the data. An important aspect of experi-
mental design is to distinguish between actual and non-speciﬁc
binding, in the data analysis, by referencing against parallel sur-
faces (Navratilova and Hopkins, 2010). On instruments with mul-
tiple biosensor channels, parallel immobilisation of the target
protein, reference proteins and the inclusion of a blank channel as a
reference surface is recommended. The shape of the sensorgram
itself also provides important information on whether a binder is
likely to be genuine or non-speciﬁc.
The false negative data detection rate is determined by the
sensitivity of the assay set-up to detect a true binding event and the
sensitivity of the biosensor instrument itself. The latest generation
of SPR biosensors instruments can detect small molecules with
molecular mass as low as 50 Da. However, the detection limit is a
function of the density of active protein immobilised on the surface.
The activity of the surface is represented by the maximum binding
response (Rmax) of ligand bound to the immobilised protein upon
saturation of all binding sites on the surface. The magnitude of Rmax
that can be recognised as the minimal detection level depends
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The minimum detection limit for identifying fragment hits by
SPR not only depends on the sensitivity of the instrument, but also
the noise of fragment binding responses. In afﬁnity determination
experiments, each compound (or fragment) is injected in a con-
centrations series separated by blank injections of buffer, to enable
the subtraction of the injection drift of the system in order to obtain
good quality responses. In the design of fragment screening ex-
periments, blanks are usually injected at every eight or more cycles
of fragment injections, to increase the overall throughput of the
screening (Fig. 1). However, the lower number of blank injections
can introduce issues with drift in the referencing or sample
carryover and may therefore result in increased noise of responses
for both binders and non-binders. Determining the behaviour of a
fragment in a dose response experiment can identify compounds
with super-stoichiometric behaviour, which can be a symptom of
non-speciﬁc binding.
The ligand's afﬁnity to the immobilised target protein and the
molecular mass detection limit of the biosensor instrument also
contribute to the sensitivity of the assay. To saturate the binding
sites on the surface, the fragment has to be ideally injected at a
signiﬁcantly higher concentration than its binding afﬁnity. How-
ever, as fragments may have binding afﬁnities in the high micro-
molar to millimolar range it may not be practically feasible to
saturate the protein surface with the fragment. A further compli-
cation that limits high concentration screening is the common
observation that many fragments may aggregate and bind non-
speciﬁcally at high concentrations. Therefore, for fragments, the
responses may be measured at concentrations at or far below their
binding afﬁnities. The Req equation can be used to estimate the
afﬁnity cut off for fragments to be detected at equilibrium (Req)400 500 600 700
ction
Positive control at 
the end of screen
nts at 50 uM fragments at 150 uM
ilibrium for fragments binding to the kinase SAP2K protein. Control compounds were
w) and a positive control was also injected in concentration series at the beginning of
trations 16.6, 50 and 150 mM (red, green and black squares). The noise of the responses
ch fragment at all three concentrations provides valuable information to distinguish
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screening concentration (c).
Req ¼ RMAX  cKD þ c
The Req equation determines that if the signal-to-noise ratio sets
the cut-off for binders and non-binders at 5 RU, the screening
concentration is 150 mM, and the Rmax is 25 RU, it is possible to
detect all compounds with afﬁnities KD < 600 mMwith conﬁdence.
However, the detection limit can be increased by increasing the
Rmax, by immobilising a high density of active protein on the
biosensor surface. The ability of well designed SPR assays to detect
binders with binding afﬁnities far above the actual screening con-
centration enables screens to be run at lower concentration than
commonly used in many other fragment screening methods. The
advantage is that, by screening fragments at lower concentrations,
much of the non-speciﬁc binding events that are observed during a
screening run at higher concentrations can be eliminated.
A further consideration in assay design is that some fragments
have a high refractive index that can add to the noise level due to
mismatch of refractive indexes between blanks and samples.
However, this can be minimised by performing ‘clean screens’ to
remove potentially problematic fragments. Additionally, the sol-
vent dimethylsulfoxide (DMSO), which is required to maintain
solubility of fragments during screening, has a high refractive index
and can be major source of false positives if the concentration is not
matched accurately between the samples and running buffer
(Papalia et al., 2006). Overall, the minimal level of detection of
fragment hits in a screen, based on the RU response, has to be
adjusted for each screen separately, based on binding of positive
and negative controls during the screen.5. GPCR fragment screening
SPR fragment screening has a wide range of applications for the
screening of diverse soluble proteins. However, the most advanced
application is its use for fragment screening against membrane
protein drug targets, such as guanine nucleotideebinding protein
coupled receptors (GPCRs). GPCRs represent an important thera-
peutic target class as they are involved in the regulation of a variety
of biological processes, such as; inﬂammation, neurotransmission,
cellular metabolism, differentiation, growth, and secretion. In fact,
around 30% of all marketed drugs target GPCRs (Overington et al.,
2006). Despite their critical importance, application of biophysical
and structural methods, and hence fragment based drug discovery,
to GPCRs has been limited, largely because of their low expression
levels and instability in detergent solutions.
Traditionally, hit identiﬁcation for GPCR targets has relied upon
cell-based assays measuring downstream signalling responses, or
ligand binding assays measuring displacement of the orthosteric
ligand, coupled with high-throughput screening (HTS) of large li-
braries of compounds (Houston et al., 2008). Evidently, this
approach has successfully delivered compounds that have made it
to themarket; however the majority of these drugs act via a narrow
range of receptors; mostly family A receptors that are activated by
small molecules (Congreve et al., 2011a). On the other hand, hit
identiﬁcation for many clinically relevant and validated targets,
such as peptide and protein hormone binding receptors, has been
challenging. In the past decade, only ten ﬁrst in class small mole-
cule GPCR drugs have been brought to market (Congreve et al.,
2011a). Furthermore, it is often difﬁcult to achieve receptor sub-
type speciﬁcity; therefore the discovery of small molecules with
novel mechanisms of action, such as allosteric modulators, could be
beneﬁcial.Fragment based drug discovery could represent a powerful
alternative compared to traditional HTS approaches for the dis-
covery of novel GPCR ligands. As discussed previously, fragment
screening allows greater sampling of chemical space and identiﬁes
low afﬁnity, ligand efﬁcient hits as starting points for the devel-
opment of high-afﬁnity compounds (Hopkins et al., 2004). High
concentration screening coupled with conventional ligand
displacement assays has been used for the fragment screening of
several receptors (Verheij et al., 2011; Stoddart et al., 2012), and
revealed remarkable similarities between the G protein-coupled
receptor histamine H-4 and the ion channel serotonin 5-HT3A
(Verheij et al., 2011). However, these assays often lack the sensi-
tivity required to detect weakly binding fragments, only detect
compounds that compete with the orthosteric ligand, and the high
screening concentration often leads to artefacts in the data. To
detect suchweak binding, biophysical techniques such as NMR, SPR
or X-ray crystallography are often employed. However, application
of these techniques to membrane proteins is often challenging due
to difﬁculties in obtaining sufﬁcient amounts of pure, stable and
functionally folded protein. In this context, SPR represents an
attractive option for the fragment screening of GPCRs since the
protein requirements are less than that of NMR or X-ray crystal-
lography. Additionally, it is possible to capture receptors directly
from crude solubilisation extracts, avoiding lengthy puriﬁcation
procedures during which functionality may be lost. SPR can also be
used to screen for solubilisation conditions that increase receptor
stability and functionality (Navratilova et al., 2005). Recently,
fragment screening by SPR has been applied to both thermo-
stabilised GPCRs (StaR®s) (Congreve et al., 2011b; Christopher et al.,
2013) and wild-type tagged receptors (Navratilova et al., 2011;
Aristotelous et al., 2013).
6. Fragment screening of stabilised GPCRs by SPR
Fragment screening of two thermostabilised receptors (StaR®s),
the adenosine A2A receptor and the b1 adrenergic receptor, has
recently been achieved using SPR (Congreve et al., 2011b;
Christopher et al., 2013). StaR®s are GPCRs that have been engi-
neered to improve their thermostability by introducing a number of
point mutations (Magnani et al., 2008; Serrano-Vega et al., 2008;
Shibata et al., 2009; Robertson et al., 2011). During development of
a StaR, the receptor is stabilised in either the agonist or inverse
agonist/antagonist conformation in complex with a suitable ligand.
These receptors can be produced in greater quantities and show
increased stability in detergent solutionwhen comparedwithwild-
type receptors. Therefore, generation of StaRs enables application
of biophysical techniques, and hence FBDD, to GPCRs.
In the case of the adenosine A2A receptor (A2AR), the StaR con-
tained four point mutations; A54L, T88A, K122A and V239A
(Magnani et al., 2008). Both afﬁnity-puriﬁed and solubilised StaRs
were captured on a charged NTA sensor chip via a C-terminal His-
10 tag (Congreve et al., 2011b). Binding of the antagonist, xanthine
amine congener (XAC), demonstrated that capture from crude
solubilisation mixtures alone produced an active A2AR surface that
could be used to characterise antagonist binding, whilst elimi-
nating the afﬁnity-puriﬁcation step. A panel of around 80 xanthine
derivatives and unrelated compounds (136e194 Da) were screened
at a single concentration of 200 mM and eight of these (~10%) were
identiﬁed as potential hits with afﬁnities ranging from 10 mM to
5 mM. This study demonstrated that SPR could be used to reliably
detect fragment-sized hits and weak binders for stabilised GPCRs.
Following this proof of concept study, it was shown that frag-
ment screening using SPR can be integrated into a true FBDD
approach to identify novel high afﬁnity leads for the b1-adrenergic
receptor (b1AR) (Christopher et al., 2013). Thermostabilised b1AR
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(Serrano-Vega et al., 2008). The immobilisation protocol involved
capture-coupling of receptors with C-terminal His-10 tags and a
“displacement regeneration” step, involving injection of a weak
afﬁnity compound, was included to regenerate the surface (Rich
et al., 2011). A panel of approximately 650 fragments were
screened in parallel against the b1AR and A2AR StaRs at a single
concentration of 50 mM. A subset of fragments that bound more
signiﬁcantly to b1AR than A2AR were then re-tested in a 2-fold
dilution series starting at 150 mM. Among these fragments were
arylpiperazine hits 7 and 8, which were estimated to have good
binding afﬁnities and ligand efﬁciency (KD ¼ 16 mM and 5.6 mM,
LE ¼ 0.41 kcal/mol/non-hydrogen-atom and 0.48 kcal/mol/non-
hydrogen-atom, respectively). A set of analogues of a similar size
and complexity were then screened in an orthogonal radioligand
membrane binding assay with wild-type b1AR; all had high ligand
efﬁciencies and moderate to high afﬁnity.
Although recent advances in the availability of GPCR crystallo-
graphic information have enabled the use of structure based drug
design strategies for GPCRs (Congreve et al., 2011a), the structure of
human b1AR has not yet been solved. Therefore, to complement the
binding information, the fragments were docked into the liganded
structure of turkey b1AR (Warne et al., 2012), which is 82% identical
in the transmembrane and loop regions and 100% identical in the
ligand binding pocket compared to human b1AR. It is particularly
challenging to dock fragments into a receptor binding site due to
their small size and numerous potential binding modes; therefore a
complete druggability analysis of the binding sitewas carried out to
identify the region most likely to be occupied by the fragment. This
approach enabled a structure-based approach to select additional
compounds and expand SAR in the series. Two high afﬁnity and
ligand efﬁcient fragments were identiﬁed; indole 19 and quinolone
20. These were co-crystalized with the stabilised b1AR and resulted
in structures determined to 2.8 and 2.7 Å respectively. Interestingly,
neither structures showed the change in rotamer conformation of
Ser2155.46 that is usually observed when a partial/full agonist is
bound (Warne et al., 2011). This may suggest that the fragments are
antagonists, although this remains to be determined in a functional
assay. This example demonstrates how SPR can be used as aFig. 2. Design of GPCR biosensor assay. 1) Expression of a C-terminally C9-tagged GPCR in a
capturing antibody on the carboxymethyldextran matrix that coats the sensor chip surface a
antibody. 4) Activity binding tests performed using conformation-dependent probes.primary fragment screening technique for stabilised GPCRs, as well
as how orthogonal assays and receptor modelling can then be used
to optimise these fragments. Additionally, the use of stabilised re-
ceptors has allowed the binding mode of the resulting high afﬁnity
fragments to be determined by X-ray crystallography.
A limitation of using thermostabilised receptors is that the re-
ceptor is stabilised in the agonist/antagonist bound conformation,
which alters the pharmacology of the receptor. For example,
antagonist stabilised A2AR has been shown not to bind agonists and
the agonist stabilised receptor binds antagonists with a ﬁve-fold
lower afﬁnity than that of the wild-type receptor (Magnani et al.,
2008; Robertson et al., 2011). Therefore, an understanding of the
receptor's pharmacology and desired pharmacological proﬁle is
required early on in the drug discovery process. A known ligand
must also be available to aid the stabilisation process; this could be
limiting when there are no tool compounds available. The process
of generating a StaR may also be time consuming, as hundreds of
point mutations are initially tested, followed by recombination
experiments to identify the optimal combination of stabilising
mutations. Furthermore, reducing conformational ﬂexibility could
mean that compounds acting by novel mechanisms could be
missed in the screening process. However, there is evidence that it
allosteric fragments can be identiﬁed using StaRs by target immo-
bilised NMR screening (TINS) (Chen et al., 2012).7. Fragment screening of wild-type GPCRs by SPR
As well as utilising SPR as a primary fragment screening tech-
nique for stabilised GPCRs, two examples of SPR screening of wild-
type receptors, each employing different immobilisation strategies,
have been reported (Navratilova et al., 2011; Aristotelous et al.,
2013). One immobilisation approach using solubilised receptors is
shown in Fig. 2. Screening against the wild-type receptor could be
advantageous as the receptor retains its native pharmacology; for
example, immobilised wild-type CCR5 has been shown to bind
agonists and antagonists with afﬁnities in agreement with those
determined for the membrane associated receptor (Fig. 3)
(Mansﬁeld et al., 2009). However, optimising solubilisation andmammalian cell line. 2) Detergent-solubilisation of GPCR 3) Immobilisation of a 1D4-
nd capture of a detergent-solubilised GPCR expressed with a C-terminal tag by the 1D4
Fig. 3. SPR analysis of GPCR ligands. SPR measurement of the binding kinetics of chemokine receptor 5 (CCR5) ligands binding to wild type solubilised CCR5. Sensorgrams of the
binding of antagonists (e.g. maraviroc and UK-438235) and agonist (UK-107543) to CCR5. Red lines represent kinetic ﬁt.
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due to a lack of stability upon removal from the membrane.
Navratilova et al. have developed a high-throughput direct-
binding SPR screening assay for wild-type CCR5, which provided
evidence that fragment screening of wild-type receptors is tech-
nically feasible (Navratilova et al., 2011). The immobilisation
strategy utilises a highly speciﬁc interaction between the ﬁnal nine
C-terminal amino acids of rhodopsin (C9 tag) and the 1D4 antibody
(Navratilova et al., 2005). The 1D4 antibody is immobilised using
amine coupling and the wild-type receptor, expressed with a C-
terminal C9 tag, is captured directly from the solubilised cell pellet.
Solubilisation conditions can also be optimised using SPR; aFig. 4. Experimental set-up for ligand screening on CCR5 G-protein-coupled receptor. CCR5
sensor surface. One-ﬂow cell carried active CCR5, reference ﬂow-cells contained 1D4 mAb o
over all ﬂow cells to determine binding.systematic detergent/lipid screen is performed to identify condi-
tions that maximise the amount of receptor solubilised, whilst
maintaining ligand binding ability (Navratilova et al., 2005). This
protocol enables puriﬁcation and immobilisation of the receptor in
a single step.
To reduce the effect of non-speciﬁc binding, and therefore
reduce the number of false positives identiﬁed, it is important to
use a suitable reference surface, particularly when immobilising
from a crude solubilisation mixture. Suitable surfaces may include
inactive membrane protein, solubilised in a deactivating detergent;
an unrelated receptor, as demonstrated by Christopher et al., or
receptors where the binding site is blocked by a high afﬁnity ligand.was solubilised and captured via a C-terminal C9 tag onto 1D4 mAb immobilised on the
nly and also CCR5 with binding site blocked by maraviroc. Ligands were then injected
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false positives with the risk of eliminating a compoundwith a novel
mechanism of action; i.e. allosteric binders which may bind to the
‘blocked’ receptor or fragments that also bind to an unrelated re-
ceptor. Two reference surfaces were included in the CCR5 screen;
1D4 antibody alone and 1D4 with CCR5 captured but blocked with
the tight-binding antagonist, maraviroc (Navratilova et al., 2011)
(Fig. 4). Two hundred compounds were prioritised from a library
containing over 90,000 compounds by Bayesian activity modelling.
The majority of these compounds were expected to bind to the
same site as maraviroc, making the blocked receptor a suitable
reference surface. Five novel ligands were identiﬁed from the
screen (KD ¼ 8 mMe49 mM), the binding of which was blocked by
maraviroc (Fig. 5).
The ability of the assay to detect compounds binding to
allosteric sites was also tested. Two pyrazinyl sulphonamide
CCR4 antagonists with weak afﬁnity for CCR5 were included in
the screen; mutagenesis studies have shown that these com-
pounds bind to a distinct intracellular allosteric site on the
chemokine receptors (Andrews et al., 2008). Interestingly, these
compounds showed an increased response for maraviroc bound
CCR5 compared to apo CCR5, although the KD was similar in the
presence and absence of maraviroc (Fig. 5). This shows that theFig. 5. SPR sensorgrams of novel CCR5 ligands. Compounds A to G identiﬁed from the SPR
CCR4 ligands which show binding to CCR5. Compounds F and G show an increased respons
presence and absence of maraviroc.SPR direct binding assay is capable of detecting allosteric com-
pounds, although care needs to be taken not to exclude these as
‘non-speciﬁc binders’ if a blocked receptor is used as a control
surface.
Most of the fragments screened against CCR5 had molecular
weights between 260 Da and 350 Da, so ﬁtted the ‘rule of three’
concept for fragment library selection but were larger than many
commercial fragment libraries (Fig. 6). The sensitivity of the assay
would need to be increased to enable the detection of fragments
found in typical fragment libraries, with molecular weights be-
tween 150 and 250 Da. This could be achieved by increasing the
amount of active receptor on the surface by; optimising solubili-
sation conditions, increasing receptor expression levels or
exploring alternative capture methods.
Recently, a fragment library with an average molecular weight
of 187 Da was successfully screened against the b2-adrenergic re-
ceptor (b2AR) using a different immobilisation approach
(Aristotelous et al., 2013). The wild-type receptor was expressed in
Sf9 cells and puriﬁed before being captured on a charged NTA
sensor-chip via a C-terminal His-10 tag (Fig. 7). The pharmacolog-
ical activity of the immobilised receptors was then characterised by
measuring the binding of an agonist and antagonist, fenoterol and
alprenolol respectively (Fig. 7); the afﬁnity which correlated well toscreen bound to active and maraviroc ‘blocked’ CCR5. Compounds F and G are known
e for maraviroc bound CCR5 compared to apo CCR5, although the KD was similar in the
Fig. 6. CCR5 ligands. Chemical structures and binding afﬁnities (KD) of novel CCR5 ligands discovered during SPR screening. The average number of heavy atoms for compounds A to
E is 23. The mean molecular weight of 200 compound library screened in this experiment was 362Da.
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et al., 2013; January et al., 1997).
A fragment library containing 656 fragments with molecular
weights between 94 and 341 Da (7e24 heavy atoms) was screened
at a single concentration against immobilised b2AR (Fig. 8). As with
CCR5, two reference surfaces were utilised to reduce the rate of
false positives; a blank reference surface and b2AR pre-incubated
with a slow off rate antagonist, BI-167107. Eighty one fragments
were identiﬁed as potential hits and tested at six concentrations
between 1.2 and 300 mM; ﬁve were conﬁrmed with afﬁnities
ranging from KD ¼ 17 nM e 22 mM (Fig. 9). The effect of differentFig. 7. b2 adrenergic receptor SPR screen. (a) SPR sensorgrams of the antagonist alprenol
receptor. Red lines represent kinetic ﬁt. (b) Experimental set-up for fragment screening on th
the N-terminus and histidine 10 (His-10) tag at the C-terminus was generated for baculov
captured via the His-10 tag on an NTA sensor chip. The b2 receptor was pre-incubated with a
binding site-blocked state).detergents, DDM and MNG, on binding of these fragments was also
tested and found to be minimal.
A radioligand competition binding assay suggested that all ﬁve
fragment hits occupied the orthosteric binding site as they showed
competitive inhibition of [125I]-cyanopindolol. This may suggest
that the fragments bind in the orthosteric binding pocket, however
allosteric compounds can also displace the orthosteric ligand via
conformational changes. The ligand binding pocket of b1AR and
b2AR are highly conserved; therefore the selectivity of these frag-
ments was examined using a radioligand competition binding
assay for b1AR. Four of the fragments showed nonselective binding,ol and the agonist fenoterol binding to immobilised, wild-type human b2 adrenergic
e human b2 adrenoceptor. A human b2 adrenoceptor construct containing a FLAG tag at
irus expression in Sf9 cells. The puriﬁed and solubilised human b2 adrenoceptor was
slow-off-rate agonist BI-167107 to create a control/reference target receptor (i.e. ligand
Fig. 8. Responses per injection measured at equilibrium for fragments binding b2 adrenergic receptor. (a) Overlay of sensorgrams of fragments binding to the active b2 adrenergic
receptor (green), deactivated receptor (pink), blank surface (blue). (b) Datapoints collected from each binding sensorgram before the end of the injection plotted versus fragments.
(c) and (d): example of binding sensorgrams collected for two fragment hits that were selected for further evaluation. The colour of each sensorgram corresponds to the surface used
for data collection as described for ﬁgure a.
Fig. 9. b2 adrenergic receptor fragment hits. Chemical structures and SPR sensorgrams of Five b2 adrenergic receptor fragment hits (A to E) were conﬁrmed with afﬁnities ranging
from KD ¼ 17 nM e 22 mM. Red lines represent kinetic ﬁt. The right-side inserted graphs for fragments D and E represent equilibrium ﬁts.
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selectivity towards b2AR. Furthermore, when the fragments were
screened against a panel of 27 receptors, fragment A was shown to
be relatively selective for b1AR. Interestingly, when tested in
functional assays, all of the fragments inhibited isoproterenol-
induced responses and none displayed agonistic activity, despite
the assay being capable of detecting agonist binding, as demon-
strated by fenoterol binding. Structure activity relationship (SAR)
data was also generated for three of the fragments and a small
number of fragment A analogues using the SPR assay. This revealed
some chemical features responsible for the high-afﬁnity of frag-
ment A (KD ¼ 39 nM, LE ¼ 0.45 kcal/mol/nonhydrogen-atom),
which could be used to grow and optimise the fragment. This piece
of work provides evidence that it is possible to utilise SPR for the
fragment screening of wild-type GPCRs to identify high afﬁnity,
selective fragment starting points for drug discovery. It is also
possible to further characterise binding of the fragments and
generate SAR data in the absence of crystallographic information
which, despite recent advances, is often lacking for GPCRs.
Generally, the limitations of measuring the kinetics of the rate of
association and dissociation for fragments is more difﬁcult than
for measuring interactions with large analytes, such as proteins,
due to the small signal observed for fragments. Additionally, frag-
ments often have fast dissociation rates, which may be outside the
limits of detection; although some fragments may also exhibit
slower off-rates. On a modern instrument such as the Biacore T200
the limits of detection are an association rate of 1  103 e
5  107 M1 s1 and a dissociation rate of 1  105 e 1 s1. To
measure the kinetics of small molecules, a high stability of the
surface is requiredwith no drift of the baselinemeasurements. Zero
baseline drift is usually difﬁcult to achieve for membrane proteins,
as capture via a His-tag is not 100% stable. Therefore, very slow off-
rates less than 105 s1 may not be accurate. For molecules with
especially fast on-rates and slow off-rates, the on-rates are usually
inﬂuenced by mass-transport due to the mechanics of ﬂow cell
conﬁgurations in SPR biosensors. To minimise mass transport ef-
fects, protein density needs to bemaintained at a very low level and
the ﬂow rate increased to enable the molecule to be presented at
the binding site faster than the on-rate. This can be problematic for
GPCRs as it is not usual for 100% of the protein to be active, and
initially it is difﬁcult to estimate how much protein is required to
achieve the appropriate immobilisation levels to obtain good
quality data and minimal mass transport effects. Therefore, these
parameters, such as immobilisation levels and ﬂow rate, need to be
optimised during assay development. However, the shape of the
binding sensorgram observed for small molecules binding to the
target can be informative as to whether there is possibility of mass
transport or not. Usually mass transport inﬂuenced association
does not have curvature in the data line a (i.e. it is a straight line) or
even has sigmoidal shape if it is heavily mass transport limited.8. Conclusion
In summary, surface plasmon resonance has emerged in recent
years as one of the most popular and versatile methods for frag-
ment screening. Practitioners have employed SPR biosensor inter-
action analysis to screen fragment libraries and to conﬁrm the
binding of bioactive compounds in fragment screening experi-
ments. In addition to providing accurate information on the afﬁnity
of a molecular interaction, SPR analysis can also provide kinetic
data, and when the experiments are designed correctly, thermo-
dynamic data. One of the most exciting developments in fragment
based drug discovery in recent years has been the use of SPR for
fragment screening against membrane protein drug targets; suchGPCRs. Although analysis of GPCR-ligand interactions using SPR has
been against isolated receptors, the pharmacological measure-
ments of afﬁnity and kinetics for GPCR ligands are very close to
those observed by cell based methods. Moreover, afﬁnity and ki-
netics can be measured in the same experiment in label-free
manner. The label-free methodology of SPR analysis also enables
both orthosteric and allosteric ligands to be detected. Thus applying
biophysical methods, such as SPR, to measure the binding of low
afﬁnity, low molecular weight fragment compounds to target
proteins enables the execution of fragment-based drug discovery
for GPCRs.
A number of SPR fragment screens against GPCRs have now
been published and further conﬁdential projects are being under-
taken in industry. The two main approaches to SPR fragment
screening, published thus far, are the use of thermostablised GPCRs
and solubilised wild type receptors. Thermostabilisation of GPCRs
reduces the complexity of assay development compared to using
native receptors; however this is at the cost of losing some func-
tional conformations. Recently, SPR fragment screens against
tagged-native sequence GPCRs have been developed using a sol-
ubilisationmethodology, whichmaintains the full range of receptor
functionality. However, these examples represent only a few well-
characterised GPCRs and the methods are not yet routinely
applied to many other GPCR targets. The barriers to routine appli-
cation of SPR to GPCRs are overexpression of functional GPCRs,
puriﬁcation of functional and stable receptors and immobilisation
of a high density of functional receptors on the biosensor surface.
However, if these assay development issues can be overcome; there
is promising evidence that SPR and fragment screening will be an
integral part of GPCR drug discovery in the future.References
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